Ophthalmology Times, in a feature article about new and different therapies emerging through the uveitis pipeline, describes a novel suprachoroidal-injection technique beginning developed by Clearside Biomedical (NASDAQ:CLSD) using a proprietary formulation of triamcinolone. In a Phase 2 trial in patients with macular edema secondary to uveitis, results demonstrated a significant reduction in macular edema, with improvements in vitreous haze and no corticosteroid-related increases in intraocular pressure.
“Suprachoroidal delivery of corticosteroid may be a potential approach to consider in the future,” Dr. Quan Dong Nguyen, professor of ophthalmology at Stanford University, said in the article.
A phase 3 trial of the technology is ongoing.
The article can be viewed here.